Search Results
Aug 31, 2026, 15:10 ET Has Anyone Tried Gundry MD Vital Reds? Read Reviews, Ingredients, Benefits & More
✝ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.*Individual results
More news about: Gundry MD
Aug 31, 2026, 13:04 ET Memorial Cancer Institute among first in South Florida to acquire breakthrough drug to treat pancreatic cancer
Broward County, Florida to obtain daraxonrasib, a drug representing one of the most significant breakthroughs in pancreatic cancer treatment in decades. This breakthrough treatment for pancreatic cancer has since received approval from the U.S. Food and Drug Administration (FDA).
More news about: Memorial Cancer Institute
Aug 31, 2026, 12:03 ET Probably Genetic Awarded Up to $10M ARPA-H Contract to End the Rare Disease Diagnostic Odyssey with AI
patients. Beyond diagnosis, this data will form the backbone of multi-omic phenotype models that link real-world evidence to disease biology and give drug developers insights needed to identify targets, stratify patients, and design clinical trials.
More news about: Probably Genetic
Aug 31, 2026, 11:57 ET Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with
More news about: BioArctic
Aug 31, 2026, 11:56 ET Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with
More news about: BioArctic
Aug 31, 2026, 11:19 ET Scientology Network's International Overdose Awareness Marathon Highlights Drug Prevention Through Education
inspiring greater awareness and action. The marathon features the Foundation for a Drug-Free World, whose grassroots network of volunteers provides factual drug education that helps people make informed decisions and live drug-free.Among the day's programming are episodes of Scientology Network's original
More news about: Church of Scientology International
Aug 31, 2026, 10:31 ET Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight
non-opioid analgesics, regenerative medicine, and disease-modifying osteoarthritis drugs (DMOADs). Advances in pain pathway modulation, intra-articular drug delivery, and cell-based regenerative therapies are creating opportunities to address both pain symptoms and disease-related structural damage. In
More news about: DelveInsight Business Research, LLP
Aug 31, 2026, 10:30 ET Xenograft Model Selection and Standardization Across CDX, PDX, Humanized, and Organoid-Derived Models in Preclinical Cancer Research
headquartered in Austin, Texas, providing xenograft efficacy studies, pharmacology and PK/PD characterization, toxicology, and IND-enabling studies for oncology drug development. The company maintains CDX, PDX, orthotopic, humanized, and organoid-derived models across major tumor types.Altogen Labs
More news about: Altogen Labs
Aug 31, 2026, 10:15 ET Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™
Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Sequencing, Bioinformatics), Applications (Drug Discovery, Tissue Regeneration, Biofuel, Food, Agriculture, Consumer Care, Environmental) - Global Forecast to 2029About MarketsandMarkets™ MarketsandMarkets™
More news about: MarketsandMarkets
Aug 31, 2026, 09:00 ET EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
The financing follows the U.S. Food and Drug Administration's (FDA) acceptance of the New Drug Application (NDA) for lonafarnib for the treatment of chronic hepatitis D (CHD), a serious life-threatening liver disease caused
More news about: EIT Pharma
Aug 31, 2026, 09:00 ET Sophos IRB Launches as the First Independent Central IRB Company Dedicated to Oncology
is value in bringing the same degree of specialization to ethical and regulatory review that sponsors increasingly expect across the rest of oncology drug development. Sophos was founded around that premise."For Sophos, oncology is not a service line or one therapeutic area among many; it is the
More news about: Sophos IRB, Inc.
Aug 31, 2026, 09:00 ET Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
the significant unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise.
More news about: Convergen
Aug 31, 2026, 08:45 ET NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
post-approval as required.A parallel path to earlier access in Canada. NeuroSense has completed the pre-New Drug Submission process with Health Canada and is preparing a New Drug Submission for PrimeC, which the Company continues to target for December 2026. If accepted and ultimately approved,
More news about: NeuroSense
Aug 31, 2026, 08:40 ET COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
optimization and PDEs-the mathematics powering everything from robotics and Physical AI, weather prediction to plasma physics, chip design, new materials and drug discovery, and real-time mission-critical decision-making.From Technology Validation to Commercial DeploymentLightSolver has moved
More news about: CollPlant
Aug 31, 2026, 08:30 ET Understanding Placebo Response: Improving Signal Detection in MDD Trials, Upcoming Webinar Hosted by Xtalks
The featured speakers will discuss how study design, patient selection, blinding, endpoint selection and rating practices can influence the observed drug-placebo difference. Attendees will also explore how participant-, rater-, site- and study-level data can help identify risks to endpoint quality and
More news about: Xtalks
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
ESMO 2026 in October. The Company also expects to reach consensus with global regulatory authorities including the U.S. Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), on the global Phase III registrational trial protocol
More news about: CStone Pharmaceuticals
Aug 31, 2026, 08:15 ET New Data at ESC Congress 2026 Validate Caristo's FAI-Score™ Biomarker and Highlight Potential Non-Contrast Cardiac CT Opportunity
future applications and are distinct from Caristo's currently available clinical portfolio:CaRi-Heart® has received U.S. Food and Drug Administration (FDA) De Novo marketing authorization (DEN250042) and is the first and only solution to quantify coronary inflammation from routine coronary
More news about: Caristo Diagnostics
Aug 31, 2026, 08:07 ET SHARx Warns PBM Rebate Reform May Move Money Without Lowering Employer Costs
with Caremark, resolving antitrust case against second drug middleman.U.S. Department of Labor, U.S. Department of Health and Human Services, & U.S. Department of the Treasury. (2024). Prescription drug spending, pricing trends, and premiums in private health insurance
More news about: SHARx
Aug 31, 2026, 08:05 ET Wisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation
revision or removal surgeries.The firm's lawsuits also challenge how spinal cord stimulators have evolved after their original U.S. Food and Drug Administration (FDA) approvals. Plaintiffs allege that manufacturers made extensive changes involving software and firmware, battery systems,
More news about: Wisner Baum
Aug 31, 2026, 08:05 ET TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations
More news about: TransCode Therapeutics, Inc.
Aug 31, 2026, 08:00 ET T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
cell therapy MT027 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma. MT027 had previously received FDA Orphan Drug Designation (ODD) for the treatment of recurrent high-grade glioma, and clearance from
More news about: T-MAXIMUM PHARMACEUTICAL
Aug 31, 2026, 08:00 ET Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
ChemPass AI™ as our core computational chemistry platform, incorporating autonomous AI agents in collaboration with Google Cloud;Signed six drug-development agreements with biotechnology companies and academic institutions;Reduced annual cash burn from ~$20.5 million in 2024 to an expected
More news about: Evogene
Aug 31, 2026, 08:00 ET Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
is currently being developed for the prevention of acute rejection in solid organ transplant recipients.The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to pegrizeprument for the prevention of organ rejection in patients receiving a liver transplant in December 2025 and
More news about: Veloxis Pharmaceuticals
Aug 31, 2026, 08:00 ET Centene Appoints New Chief Information Officer
and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans), as well as individuals and families served by the Health Insurance Marketplace.
More news about: Centene Corporation
Aug 31, 2026, 07:35 ET Trucking Hub Launches DOTConsortium.com, a Nationwide DOT Drug and Alcohol Testing Platform for Trucking Companies and Owner-Operators
is designed around the drug and alcohol compliance requirements that apply to motor carriers and commercial drivers regulated by the Federal Motor Carrier Safety Administration.The platform supports:Pre-employment drug testingRandom drug and alcohol testingPost-accident
More news about: Trucking Hub